Filtered By:
Specialty: Neurology
Condition: ALS
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 158 results found since Jan 2013.
Neuroprotective Mechanisms of Glucagon-Like Peptide-1-Based Therapies in Ischemic Stroke: An Update Based on Preclinical Research
The public and social health burdens of ischemic stroke have been increasing worldwide. Hyperglycemia leads to a greater risk of stroke. This increased risk is commonly seen among patients with diabetes and is in connection with worsened clinical conditions and higher mortality in patients with acute ischemic stroke (AIS). Therapy for stroke focuses mainly on restoring cerebral blood flow (CBF) and ameliorating neurological impairment caused by stroke. Although choices of stroke treatment remain limited, much advance have been achieved in assisting patients in recovering from ischemic stroke, along with progress of recanal...
Source: Frontiers in Neurology - March 15, 2022 Category: Neurology Source Type: research
FUS aggregation following ischemic stroke favors brain astrocyte activation through inducing excessive autophagy
In conclusion, our results reveal the important contribution of FUS aggregates in promoting astrocyte activation in stroke pathology independent of its transcriptional regulation activity. We thus propose that aggregation of FUS is an important pathological process in ischemic stroke and targeting FUS aggregates might be of unique therapeutic value in the development of future treatment strategies for ischemic stroke.PMID:35718207 | DOI:10.1016/j.expneurol.2022.114144
Source: Experimental Neurology - June 19, 2022 Category: Neurology Authors: Shusheng Wu Yuye Yin Longfei Du Source Type: research
PRISM II: Effectiveness of Dextromethorphan 20 mg/Quinidine 10 mg (NUEDEXTA(R)) for Treatment of Pseudobulbar Affect Secondary to Dementia, Stroke, or Traumatic Brain Injury: Combined Results of a Multicenter Open-Label Study (P2.225)
Conclusion: The open-label PRISM II study supports DM/Q effectiveness for PBA irrespective of underlying etiology. Study supported by: Avanir Pharmaceuticals, Inc.Disclosure: Dr. Siffert has nothing to disclose. Dr. Hammond has nothing to disclose. Dr. Alexander has nothing to disclose. Dr. Cutler has received personal compensation for activities with Abbott, AstraZeneca, Bristol-Myers Squibb, Forest, GlaxoSmithKline, Lilly, Merck, Novartis, Ortho-McNeil-Janssen, Otsuka, Pamlab, Pfizer, Shire, and Sunovion. Dr. D'Amico has received personal compensation for activities with Avanir Pharmaceuticals, Inc. Dr. Doody has receive...
Source: Neurology - April 3, 2016 Category: Neurology Authors: Siffert, J., Hammond, F., Alexander, D., Cutler, A., D'Amico, S., Doody, R., Sauve, W., Zorowitz, R., Davis, C., Shin, P., Ledon, F., Yonan, C., Formella, A. Tags: Aging and Dementia: Therapeutics Source Type: research
Amyotrophic Lateral Sclerosis (ALS)
ALS, Amyotrophic Lateral Sclerosis or Lou Gehrig's disease information sheet compiled by the National Institute of Neurological Disorders and Stroke (NINDS).
Source: NINDS Disorders: National Institute of Neurological Disorders and Stroke - October 26, 2014 Category: Neurology Source Type: research
Dynamic changes and mislocalizations of neurodegenerative disease-related proteins in mice stroke model.
In this study, we report that RBPs increased significantly compared with the sham group (*p < 0.05 and **p < 0.01 vs sham), with nuclear depletion and cytoplasmic deposition in neurons in the acute phase of cerebral ischemia. On the other hand, such nucleocytoplasmic mislocalization were not observed in astrocytes. We provide evidence of the alteration of these neurodegeneration-related RBPs after cerebral ischemia, suggesting a potential association between cerebral ischemia and neurodegenerative diseases.
PMID: 32360098 [PubMed - as supplied by publisher]
Source: Brain Research - April 27, 2020 Category: Neurology Authors: Liu X, Yamashita T, Shi X, Bian Y, Bian Z, Omote Y, Takemoto M, Hishikawa N, Ohta Y, Abe K Tags: Brain Res Source Type: research
Relationship Between Bone Mass And Muscle Weakness In Chronic Neurological Diseases (P3.036)
Conclusions: This study demonstrates greater commitment tendency to bone density in regions with weakness, compared to those without it, this could be related to disuse. This series had insufficient vitamin D. The neurologist should consider bone mass evaluation in patients with chronic muscle weakness.Disclosure: Dr. Gutierrez has nothing to disclose. Dr. Rodriguez has nothing to disclose. Dr. Garcea has nothing to disclose. Dr. Rey has nothing to disclose. Dr. Lepera has nothing to disclose. Dr. Monica has nothing to disclose. Dr. Monica has nothing to disclose. Dr. Eduardo has nothing to disclose. Dr. Berenice has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Gutierrez, M., Rodriguez, G. E., Garcea, D., Rey, R., Lepera, S., Monica, E., Monica, D., Eduardo, K., Berenice, S. Tags: General Neurology II Source Type: research
PRISM Registry: A Novel Tool To Estimate the Prevalence of Pseudobulbar Affect Symptoms (P03.215)
CONCLUSIONS: PRISM provides novel insight into PBA symptom prevalence by prospectively evaluating a large number of patients across diagnoses and clinical settings. Follow-on studies are planned.Supported by: Avanir Pharmaceuticals, Inc.Disclosure: Dr. Brooks has received personal compensation for activities with Biogen Idec, Avanir Pharmaceuticals, Acorda Therapeutics, Cytokinetics, Synapse, and the National Institute of Neurological Disorders and Stroke. Dr. Brooks has received research support from Biogen Idec, Avanir Pharmaceuticals, Cytokinetics, Neuraltus, GlaxoSmithKline, Inc., and the National Institute of Neurolog...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Brooks, B., Crumpacker, D., Fellus, J., Kantor, D., Kaye, R. Tags: P03 Multiple Sclerosis: Quality of Life and MS Symptoms Source Type: research
Effects of vitamin E on neurodegenerative diseases: an update
Acta Neurobiol Exp (Wars). 2021;81(1):21-33. doi: 10.21307/ane-2021-003.ABSTRACTVitamin E deficiency is associated with many neurological problems. Although the mechanisms of vitamin E action in neurodegenerative diseases are not clear, there are many possible mechanisms. Examples of such mechanisms are the protective effects of vitamin E against oxidative stress damage and its suppressive role in the expression of many genes involved in the development of neurodegeneration. Many studies have evaluated the relationship between vitamin E intake or vitamin E levels in body fluids and neurodegenerative diseases. Some studies ...
Source: Acta Neurobiologiae Experimentalis - May 5, 2021 Category: Neurology Authors: Mehmet Arif Icer Neslihan Arslan Makbule Gezmen-Karadag Source Type: research
